Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
Sign Up to like & getrecommendations! Published in 2018 at "Gynecologic Oncology Reports"
DOI: 10.1016/j.gore.2018.05.009
Abstract: Background Uterine serous carcinoma (USC) is a biologically aggressive variant of uterine cancer. Effective treatment options for recurrent, chemotherapy-resistant USC are extremely limited. Case We describe a 74-year-old woman with recurrent and widespread treatment-resistant disease,… read more here.
Keywords: treatment resistant; uterine serous; treatment; sacituzumab govitecan ... See more keywords
HER2 in uterine serous carcinoma: Current state and clinical perspectives.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqad056
Abstract: OBJECTIVES Uterine cancer has the highest incidence and the second-highest mortality rate among gynecologic malignancies in the United States. Although uterine serous carcinoma (USC) represents less than 10% of endometrial carcinomas, it accounts for a… read more here.
Keywords: endometrial cancer; her2; serous carcinoma; uterine serous ... See more keywords
Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2020-001379
Abstract: Objectives The role of adjuvant treatment for early-stage uterine serous carcinoma is not defined. The goal of this study was to investigate the impact of adjuvant treatment on survival of patients with tumors confined to… read more here.
Keywords: chemotherapy; uterine serous; adjuvant treatment; treatment ... See more keywords
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2021-003144
Abstract: Background Uterine serous carcinoma is a distinct histologic subtype of endometrial cancer with an aggressive phenotype, poor prognosis, and limited therapeutic options. A previous proof-of-concept phase II trial of the Wee1 inhibitor adavosertib in uterine… read more here.
Keywords: persistent uterine; uterine serous; women recurrent; recurrent persistent ... See more keywords
Abstract 2438: Loss of galectin 3 reveals its potential roles in the aggressive pathology of uterine serous carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2438
Abstract: Objective: Uterine serous cancer (USC) represents about 10% of all uterine cancers, yet it accounts for up to 40% of all uterine cancer deaths. This lethality is due in part to the highly aggressive clinical… read more here.
Keywords: cell; loss; gal3; pathology ... See more keywords
Uterine Serous Carcinoma Responds to the WEE1 Inhibitor Adavosertib.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2021-043
Abstract: The overall response rate to adavosertib was 29.4%; no biomarkers predicting response were found. read more here.
Keywords: serous carcinoma; carcinoma responds; uterine serous; wee1 inhibitor ... See more keywords
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.20.03167
Abstract: PURPOSE Uterine serous carcinoma (USC) is a distinct histologic subtype of endometrial cancer, with molecular characteristics suggesting frequent cell-cycle dysregulation paired with a high level of oncogene-driven replication stress. Adavosertib is a potent and selective… read more here.
Keywords: serous carcinoma; study; uterine serous; adavosertib monotherapy ... See more keywords
Large germline next generation (NGS) sequencing panel of uterine serous carcinoma.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e13106
Abstract: e13106Background: Genetic predisposition to uterine serous carcinoma (USC) remains unclear and has been related to Lynch Syndrome (LS) and BRCA1/2 mutations. Wide NGS panels for this condition are starting to be implemented and data remain… read more here.
Keywords: uterine serous; serous carcinoma; generation; panel ... See more keywords
Exploring molecular profiles and survival in hormone receptor-positive uterine serous carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.5579
Abstract: 5579 Background: Hormone receptor (HR) positivity has been reported as a good prognostic indicator in endometrial cancer. This study investigated estrogen receptor (ER) and progesterone receptor (PR) positivity as indicators of platinum response and improved… read more here.
Keywords: expression; hormone receptor; serous carcinoma; receptor ... See more keywords
Stage III uterine serous carcinoma: modern trends in multimodality treatment
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Gynecologic Oncology"
DOI: 10.3802/jgo.2020.31.e53
Abstract: Objective To examine outcomes in a modern treatment era for stage III uterine serous carcinoma (USC). Methods Fifty women were retrospectively identified as 2009 International Federation of Gynecology and Obstetrics stage III USC patients who… read more here.
Keywords: stage iii; era; uterine serous; treatment ... See more keywords